| Drug Name |
Stiripentol |
| Drug ID |
BADD_D02069 |
| Description |
Stiripentol is an anticonvulsant drug used in the treatment of epilepsy as an adjunct therapy along with [DB00349] and [DB00313]. This drug is currently approved in the USA, Canada, and European countries as oral tablets marketed as Diacomit. FDA approval of this drug was granted on August 20, 2018 [L4352], [F1240]. Unrelated to other anticonvulsants, stiripentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates the levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system. |
| Indications and Usage |
Indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate. |
| Marketing Status |
approved |
| ATC Code |
N03AX17 |
| DrugBank ID |
DB09118
|
| KEGG ID |
D05928
|
| MeSH ID |
C021092
|
| PubChem ID |
5311454
|
| TTD Drug ID |
D02XSA
|
| NDC Product Code |
69766-075; 42765-058; 68418-7941; 58159-069; 68418-7940; 68418-7942; 68418-7939 |
| UNII |
R02XOT8V8I
|
| Synonyms |
stiripentol | Diacomit | D-306 |
